PT  - JOURNAL ARTICLE
AU  - TOMONORI HIRASHIMA
AU  - TOMOHIRO KANAI
AU  - HIDEKAZU SUZUKI
AU  - HIROKO YOSHIDA
AU  - AKANE MATSUSITA
AU  - HIROMI KAWASUMI
AU  - SHINGO NASU
AU  - AYAKO TANAKA
AU  - NAOKO MORISHITA
AU  - KUNIMITSU KAWAHARA
AU  - YOSHITAKA TAMURA
AU  - NORIO OKAMOTO
TI  - Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors
AID  - 10.21873/anticanres.14721
DP  - 2020 Dec 01
TA  - Anticancer Research
PG  - 6971--6978
VI  - 40
IP  - 12
4099  - http://ar.iiarjournals.org/content/40/12/6971.short
4100  - http://ar.iiarjournals.org/content/40/12/6971.full
SO  - Anticancer Res2020 Dec 01; 40
AB  - Background/Aim: We retrospectively investigated the significance of pre-treatment interferon-gamma release (IGR) as a biomarker for predicting the efficacy of immune checkpoint inhibitor treatment (ICI-tx). Patients and Methods: This study included non-small-cell lung cancer patients who received ICI-tx between January 1, 2016 and April 30, 2019. IGR was measured using the positive control of an enzyme-linked immunosorbent assay. We defined the pre-treatment cut-off level of IGR as 10 IU/ml. Results: Fifty-four patients were divided into two groups; those with an IGR ≤10 IU/ml (lower group: LG) (n=15) and those with >10 IU/ml (higher group: HG) (n=39). The time to treatment failure (TTF) in the HG was significantly longer than that in the LG. In multivariate analyses, C-reactive protein and IGR levels were significant risk factors for TTF. Conclusion: Pre-treatment IGR level of >10 IU/ml is recommended to identify those patients who will respond favourably to ICI-tx.